ProCE Banner Activity

Expert Guidance for Managing Triple Class–Refractory MM (Excluding BCMA-Targeted Therapies)

Slideset Download
Download this slideset based on content from the annual CCO/IMF satellite symposium at ASH on treatment options for patients with heavily pretreated, relapsed/refractory multiple myeloma, excluding BCMA-targeted agents.

Released: December 15, 2021

Expiration: December 14, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Genentech, a member of the Roche Group

GlaxoSmithKline

Janssen administered by Scientific Affairs

Karyopharm Therapeutics

Oncopeptides

Pfizer, Inc.

Sanofi Genzyme

Partners

International Myeloma Foundation

ProCE Banner